US FDA clearance for Joimax Vaporflex and Legato electrosurgical probes

197

 

Joimax Vaporflex
Joimax Vaporflex

Joimax has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its Vaporflex and Legato electrosurgical probes with radiowave technology for open and endoscopic spine surgery.

The Joimax electrosurgical instruments are comprised of a series of instruments to facilitate the delivery of electrical energy from a radiofrequency generator to the patient tissue for use in cutting and/or coagulation of tissue. All Vaporflex and Legato probes use radiofrequency generated by high-oscillating electrical current received from a commercially-available radiofrequency generator.

The new Vaporflex system is available in different lengths, diameters and probe tips to allow endoscopic transforaminal and interlaminar procedures. It is cleared for the use with all Endovapor/SurgiMax and SurgiMax Plus electrosurgical units, and is intended to enable an easy swap of the Triggerflex to the new Vaporflex system. The bipolar Vaporflex probes are designed to be easily adopted to the complete range of Joimax systems. All probes are offered in a kit containing a sterilisation tray, the hand piece as well as a shaft and a connection cable.

The monopolar and bipolar Legato probes are designed to support the rhizotomy procedures with the existing Multiuse, and both newly launched products MultiZyte RT for facet joint denervation and MultiZyte SI for sacroiliac joint therapy.